Recaticimab (SHR-1209) is a humanized monoclonal antibody targeting PCSK9. By binding to PCSK9, Recaticimab promotes LDL receptor stabilization and surface expression on hepatocytes, leading to reduced plasma LDL cholesterol levels. Recaticimab is under study as a therapeutic candidate for hypercholesterolemia and related cardiovascular disorders.
Purity:
95.00%
CAS Number:
[2361290-85-7]
Target:
LDLR|||Others
* VAT and and shipping costs not included. Errors and price changes excepted
